RVMD 240517 40.00C (RVMD240517C40000) Stock Options, News & Quotes

US OptionsDetailed Quotes

RVMD240517C40000

Watchlist

1.55
-1.49-49.01%

15min DelayClose May 8 16:00 ET

1.65High1.40Low

Intraday

News

Express News | Revolution Medicines Inc : Guggenheim Raises Target Price to $50 From $38
Reuters14minutes ago
Revolution Medicines Inc (RVMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Yahoo Finance05:01 ET
Express News | Revolution Medicines Inc : Leerink Partners Raises Target Price to $48 From $37
Reuters23:58 ET
Revolution Medicines, Inc. (RVMD) Q1 2024 Earnings Call Transcript
Revolution Medicines, Inc. (RVMD) Q1 2024 Earnings Call Transcript
Earnings Call Transcripts21:11 ET
Revolution Medicines Q1 2024 GAAP EPS $(0.70) Beats $(0.75) Estimate
Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.75) by 6.67 percent.
Benzinga18:21 ET
Revolution Medicines Q1 Net Loss Narrows
Revolution Medicines (RVMD) reported a Q1 net loss Wednesday of $0.70 per share, narrowing from a loss of $0.72 a year earlier. Analysts polled by Capital IQ expected a loss of $0.75. The company did
MT Newswires17:37 ET

Comments

Jerry Kronenberg

Apr 11 04:11

ColumnsRevolution Medicines Gains 10%+ on Word of Experimental Anti-Tumor Drug

$Revolution Medicines(RVMD.US)$ rose more than 10% Wednesday after the biotech firm reported the discovery and preclinical-to-clinical translation of its anti-tumor drug RMC-6236.
RVMD gained 10.6% to close at $36.50 on word of the experimental drug, which the company disclosed in the publication Cancer Discovery.
Revolution disclosed news of the drug on Tuesday shortly before the market closed, sending shares up 3.4% that da...